June 21, 2018
trial_results

Pediatric Oncology – Key Results from ASCO 2018

Pembrolizumab demonstrated durable anti-tumor activity in various tumors specially Hodgkin Lymphoma (ORR: 50%, mPFS: 12.2 months, 12 month PFS rate: 59.7%). The results indicate further study of pembrolizumab in pediatric patients with particulate interest in Lymphoma Phase 2 Study results confirms PR rate of 72% with that of phase 1 […]
June 5, 2018
financial_incentive

Strategies to Accelerate Innovation in Pediatric Space

  Why is it so difficult to develop drugs for children with cancer? What can be done to stimlate investments in the pediatric oncology space?  These questions are central to a new study published by MIT Sloan researchers that explores new business models for funding drug development to treat pediatric cancers.  The […]